![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, June 28, 2021 10:43:07 AM
Despite its general failure for head and neck cancer, I do believe after all have settled down, they should get Multikine approved for those patients who receive Multikine followed by the part of SOC (surgery and radiotherapy only without chemo) because of reasonable improvement of OS plus quality of life for patients.
As for NWBO's DCVax-L, it's the first time DCVax-L is used in p3 clinical trial built up from positive p1/2 trial;
Most importantly, we know what the results would be look like from interim blinded, blended data published in 2018 on the backdrop of no improvement of SOC for GMB for decades and improvement data uptrend observed from the followed up data presentation after the publication.
Unless the final data readout is significantly worse than the data published in 2018 and/or placebo patients (or patients who received vaccine later after progression) outlive patients of treatment arm (or patients who received vaccine earlier before progression), it's no way DCVax-L will not show significant efficacy over SOC.
As I am typing, my first buy order is shown filled at 1.52. Intended to buy more as the price is artificially pulled down for obvious reason today: psychological impact for those ignorant due to CVM's failure, despite there is nothing comparable.
Besides, cvm ceo has spared no opportunities in pumping cvm stock while our dear ceo Linda has spared no opportunities keeping quiet.
[got a tiny order filled again at 1.51 as of 10:48am]
[Plus, cvm's large financing just last week or so was very suspicious]
[got this batch of order filled at 1.50]
[more to come]
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM